A phase 1 clinical trial in patients with advanced or metastatic HER2+ tumors showed that RC48 monotherapy had promising results and was well tolerated (NCT02881190), particularly in patients with HER2-low gastric cancer [119,120] and advanced or metastatic breast cancer [121]. This evidence concerns the gene ERBB2 and gastric cancer.